Axa S.A. Uni Qure N.V. Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Feb 14, 2023	SELL	$13.15 - $20.45 $87,776 - $136,503	-6,675 Reduced 7.98%	76,925 $1.43 Million
Q2 2022 Aug 15, 2022	SELL	$13.15 - $20.45 $87,776 - $136,503	-6,675 Reduced 7.98%	76,925 $1.43 Million
Q1 2022 Feb 14, 2023	BUY	$14.54 - $21.5 $1.22 Million - $1.8 Million	83,600 New	83,600 $1.51 Million
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $1.07 Million - $1.58 Million	73,400 Added 719.61%	83,600 $1.51 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $206,447 - $367,302	10,200 New	10,200 $212,000
Q1 2019 May 14, 2019	SELL	$27.39 - $68.41 $2.55 Million - $6.37 Million	-93,046 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$22.8 - $33.93 $2.12 Million - $3.16 Million	93,046 New	93,046 $2.68 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.